The Dirty Secret of Genetic Testing: We're Still Not Sure What "Normal" Looks Like
By Sean Captain,
Fast Company
| 03. 04. 2016
Untitled Document
Getting a full readout of your entire genetic sequence promises to radically alter how we monitor our health, providing advanced warning of cancer and other diseases we may suffer and our chances of passing on those ailments. Clinical genetic testing firm Illumina is valued at nearly $23 billion, for example, while direct-to-consumer offering 23andMe is at about $1 billion. Meanwhile, the price for so-called whole genome sequencing has dropped to about $1,000.
But such whole-genome sequencing currently over-promises in several ways. One of them is a false sense of what constitutes a "normal" genome with which to compare someone's results. (The U.S. government's National Institutes of Health provides a narrow, widely used model.) The promise is best if you're white, and drops off fast for other ethnicities, like people of African origin. That’s because we simply don't have easy access to enough reference genomes, from a big enough variety of people, to understand the range of normal. Nor is there much willingness for companies that analyze genomes to look at all the varieties that are out there...
Related Articles
By Margaux MacColl, The San Francisco Standard | 09.17.2025
Designer babies are coming soon to an IVF clinic near you.
Nucleus Genomics, founded by Kian Sadeghi in 2020, when he was just 20, got its start analyzing genomes to weigh a person’s risk of everything from cancer to ADHD...
By Johana Bhuiyan, The Guardian | 09.23.2025
In March 2021, a 25-year-old US citizen was traveling through Chicago’s Midway airport when they were stopped by US border patrol agents. Though charged with no crime, the 25-year-old was subjected to a cheek swab to collect their DNA, which...
By Annika Inampudi, Science | 08.01.2025
In June, Sara* received a message asking whether she wanted to continue to participate in a massive, multicenter research project led by scientists at Aarhus University in Denmark. The iPsych study, the message said, had sequenced her genetic data from...
The Center for Genetics and Society is delighted to recommend the current edition of GMWatch Review – Number 589. UK-based GMWatch, a long-standing ally, was founded in 1998 by Jonathan Matthews as an independent organization seeking to counter the enormous corporate political power and propaganda of the GMO industry and its supporters. Matthews and Claire Robinson are its directors and managing editors.
CGS works to ensure that social justice, equity, human rights, and democratic governance are front...